REGN FY2025 EPS Estimate Raised by Cantor Fitzgerald

Key Points

• Investment analysts at Cantor Fitzgerald raised their FY2025 earnings estimate for Regeneron Pharmaceuticals to $31.81 per share, up from $30.25, while the current consensus estimate is $35.92.
• Regeneron Pharmaceuticals has received various ratings from analysts, including three Strong Buy ratings and eighteen Buy ratings, with a current consensus rating of Moderate Buy.
• The company recently declared a $0.88 per share quarterly dividend, representing an annualized dividend of $3.52 and a dividend yield of 0.6%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for shares of Regeneron Pharmaceuticals in a note issued to investors on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will post earnings per share of $31.81 for the year, up from their previous estimate of $30.25. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share.

Other analysts have also recently issued research reports about the stock. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Sanford C. Bernstein increased their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a report on Wednesday, August 27th. Morgan Stanley reiterated an "overweight" rating and issued a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Stock Up 1.1%

REGN stock opened at $569.90 on Friday. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $1,024.36. The stock has a market capitalization of $60.40 billion, a PE ratio of 14.36, a price-to-earnings-growth ratio of 1.81 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a fifty day moving average of $573.83 and a 200-day moving average of $565.52.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the business earned $11.56 EPS. The business's revenue was up 3.6% on a year-over-year basis.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the company. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management boosted its stake in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Finally, Colonial Trust Advisors acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.